News

Video

Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer

Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.

Related Videos
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.